19 results about "CD46" patented technology

The invention provides a cotton transformation event cD46-2 as well as a primer pair and a method for detecting the cotton transformation event cD46-2. The cotton plant carrying the cD46-2 transformation event comprises the event, namely the joint of an exogenous insertion DNA sequence and a cotton genome DNA sequence, on a group A chromosome 2. A detection primer can be designed by using an exogenous insertion DNA sequence and a DNA sequence of a junction region on a flanking cotton genome, and is used for specific detection of a cD46-2 event. The detection method aiming at the cD46-2 event can provide a convenient means for tracking the specific gene insertion event for the application of breeding by using the plant event, and the specific gene insertion event can be used as a molecular marker to improve the working efficiency of fiber improvement breeding by using the transformation event.

The application belongs to the technical field of biological medicine and immunology, and particularly relates to a single-domain antibody targeting cross binding of human and cynomolgus monkey CD46 and application thereof. The application utilizes alpaca to generate nanoscale antibodies, the molecular weight of which is about 15 kDa, and the nanoscale antibodies can more efficiently penetrate solid tumor tissues or cross blood-brain barrier, and the binding efficiency of the antibodies and target points is as high as possible. The 11 single-domain antibodies prepared by the application have specificity of anti-human and anti-cynomolgus monkey CD46, and in the binding detection with CD46 target proteins and CD46 overexpression cells, the binding efficiency is significantly better than that of Anti-CD46 humanization antibody, and the single-domain antibodies can be used for tumor treatment. Meanwhile, the single-domain antibodies have cross binding ability of cross species, and can be directly used for preclinical pharmacodynamics and safety evaluation, without the need of developing species-specific alternative antibodies, so that the application achieves 'one target and double effect'.

The invention belongs to the technical field of biological medicine and immunology, and particularly relates to a single-domain antibody targeting cross binding of human and cynomolgus monkey CD46 and application of the single-domain antibody. The alpaca is utilized to generate the nanoscale antibody, the molecular weight of the nanoscale antibody is about 15 kDa, the nanoscale antibody can more efficiently penetrate solid tumor tissues or cross a blood brain barrier, and the binding efficiency of the antibody and a target spot is improved as much as possible. The 11 single-domain antibodies prepared by the invention have the specificity of resisting human and cynomolgus monkey CD46, the binding potency of the 11 single-domain antibodies is remarkably superior to that of an Anti-CD46 humanization antibody in the binding detection of CD46 target protein and CD46 overexpression cells, and the 11 single-domain antibodies can be used for treating tumors. Meanwhile, the single-domain antibody disclosed by the invention has cross-species cross binding capacity, can be directly used for preclinical pharmacodynamics and safety evaluation, does not need to develop a species-specific substitution antibody, and realizes'one target and double effects'.

In various embodiments human anti-CD46 antibodies that are internalizing and enter tumor cells via the macropinocytosis pathway are provided, as well as antibody-drug conjugates (ADCs) developed from these antibodies for diagnostic and / or therapeutic targeting of CD46-overexpressing tumors.

The invention belongs to the technical field of biological medicines, and particularly relates to application of chenodeoxycholic acid in preparation of drugs for treating allergic diseases. It is found that CDCA can effectively inhibit pyroptosis and secretion of proinflammatory factors, expression of complement inhibition proteins CD46, CD55 and CD59 is remarkably up-regulated, expression of the complement inhibition proteins CD46, CD55 and CD59 is finally promoted, and occurrence and development of allergic diseases are effectively relieved. In a mouse model, CDCA can significantly improve OVA-induced food allergy symptoms, and has application prospects in treatment of allergic diseases.

The present invention relates generally to the field of disorders of complement activation. More specifically, the present invention provides methods and compositions useful for diagnosing and treating complementopathies and monitoring therapy in disease where complement inhibitors are used. In one aspect, the present invention provides a method for detecting dysregulation of the alternative pathway of complement in a patient. In one embodiment, the method comprises the steps of (a) contacting serum obtained from a patient with a composition comprising double CD46 / PIGA knockout (DKO) cells suspended in MgEGTA buffer; and (b) measuring luminescence continuously or serially over a period of time, wherein a lower luminescence related to a healthy control indicates dysregulation of the alternative pathway of complement in the patient.

In various embodiments human anti-CD46 antibodies that are internalizing and enter tumor cells via the macropinocytosis pathway are provided, as well as antibody-drug conjugates (ADCs) developed from these antibodies for diagnostic and / or therapeutic targeting of CD46-overexpressing tumors.

The invention relates to the crossing field of a gene editing technology and a veterinary biotechnology, in particular to a goat spermatogonial stem cell anti-BVDV functional target based on CD46 gene editing and application of the goat spermatogonial stem cell anti-BVDV functional target. An anti-virus cell strain is obtained by designing sgRNA of a targeted CD46 CCP1 structural domain and knocking out the gene through a CRISPR-Cas9 system. An infection experiment shows that the virus load of the delta CD46-SSCs is reduced by 90%, and the survival rate is recovered to 85%. The invention reveals that CD46 is a key receptor of goat BVDV infection for the first time, and provides a new strategy for disease-resistant breeding and targeted drug development.

The present invention provides an isolated polypeptide having a heavy chain variable region and / or a light chain variable region that specifically binds to the CD46 protein, as well as antibodies and antibody fragments comprising the heavy chain variable region and / or the light chain variable region that binds to the CD46 protein. Also provided are immunoconjugates, pharmaceutical compositions, and kits comprising the polypeptides and antibodies and antibody fragments comprising the polypeptides.

The present application relates to macropinocytic human anti-CD46 antibodies and targeted cancer therapies. In various embodiments, human anti-CD46 antibodies that are internalized via the macropinocytic pathway and enter tumor cells, as well as antibody-drug conjugates ADCs developed from these antibodies for diagnostic and / or therapeutic targeting of CD46 overexpressing tumors are provided.

A nucleic acid molecule comprising: a first polycistronic cassette comprising: TFPI (EPI / LACI), EPCR (PROCR), and thrombomodulin (THBD); a second polycistronic cassette comprising: B2M HLA-E fusion pr

The application discloses an enhanced CD46 decoy protein and application thereof in preparation of a medicine against bovine viral diarrhea virus, and belongs to the technical field of biological medicine. The application first analyzes the crystal structure of an E2-CD46 complex, determines key amino acid sites of a binding interface between E2 and CD46, and constructs a mutant with significantly improved affinity compared with a wild type. The application further constructs a dimer and a trimer with a CD46 truncated body or mutant as a monomer. The obtained high-affinity decoy proteins mCD46-12 and mCD46-13 can achieve nearly complete virus neutralization and blocking effect at micromolar concentration, can effectively competitively inhibit invasion of BVDV to host cells, provide a brand-new and efficient candidate molecule for preparation of a medicine for treating bovine viral diarrhea infection, and have great clinical application prospect and economic and social value.

An immunoassay for assisting in the diagnosis of sepsis or severe infection in a patient / subject, the assay comprising the steps of: (i) optionally contacting a test sample comprising neutrophils from the patient with an agent that permeabilises or solubilises neutrophils; (ii) simultaneously with (i) or sequentially, contacting the sample with a binding agent that binds specifically to CD64 in the sample and forms a CD64-binding agent complex a; (iii) simultaneously with (i) and / or (ii) or sequentially, contacting the sample with a second binding agent that binds specifically to a neutrophil number marker (NNM) in the sample and forms a neutrophil marker-binding agent complex b; (iv) employ the amount of complex a and complex b to determine the relative level of CD46 and of NNM in the sample.

This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine β1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and / or reduced or no endogenous α-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.

Disclosed herein are immunoconjugates comprising a CD46 binding domain and an effector agent. Also provided herein are methods of treating cancer comprising administering to a subject having cancer a pharmaceutical composition comprising an immunoconjugate comprising a CD46 binding domain and an effector agent. In one embodiment, the immunoconjugate is FOR46, which is a conjugate of the anti-CD46 antibody YS5FL linked to monomethyl auristatin E (MMAE) via a maleimidocaproyl-valine-citrulline-para-aminobenzoxycarbonyl (mc-vc-PAB) linker.

The application belongs to the technical field of biological medicine, and particularly relates to an antibody conjugated drug targeting CD46 and a preparation method and application thereof. The application is based on a single-domain antibody 31-17-1-A12 with cross binding of human and cynomolgus monkey CD46, and a high-activity cytotoxic load is connected to a cysteine position of a human immunoglobulin G1 crystalline fragment (human IgG1 Fc) connected to a C terminal of the single-domain antibody 31-17-1-A12 through site-specific conjugation technology, so as to finally prepare a novel antibody conjugated drug (Antibody-Drug Conjugate, ADC). The ADC prepared by the application has specificity of resisting human and cynomolgus monkey CD46, a drug-antibody ratio is about 4, and in the detection of killing CD46 high-expression tumor cells in vitro, the killing efficiency is significantly better than that of naked antibody without conjugated cytotoxic load, and good tumor targeted treatment potential is exhibited.

The present invention relates generally to the field of disorders of complement activation. More specifically, the present invention provides methods and compositions useful for diagnosing and treating complementopathies and monitoring therapy in disease where complement inhibitors are used. In one aspect, the present invention provides a method for detecting dysregulation of the alternative pathway of complement in a patient. In one embodiment, the method comprises the steps of (a) contacting serum obtained from a patient with a composition comprising double CD46 / PIGA knockout (DKO) cells suspended in MgEGTA buffer; and (b) measuring luminescence continuously or serially over a period of time, wherein a lower luminescence related to a healthy control indicates dysregulation of the alternative pathway of complement in the patient.

Disclosed herein are polynucleotides encoding fusion proteins, the fusion proteins comprising a vaccinia virus envelope protein, such as A13 or part thereof and at least one complement regulatory protein, such as CD35, CD55, CD59, CD46, CR1, Factor H, VCP, MOPICE, SPICE and CCPH, or a functional fragment thereof. Modified vaccinia virus vectors and vaccinia virus virions are also disclosed, as are therapeutic uses and methods for treatment of cancers and / or proliferative diseases or disorders.